Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
New Science Ventures, LLC (NSV) is a venture capital firm founded in 2004, headquartered in Connecticut with an office in London. The firm manages investments across various stages, including seed, Series A, Series B, Series C, and growth equity. NSV focuses on companies that leverage scientific innovations to meet significant market needs in the life sciences and information technology sectors.
NSV invests in early and late-stage companies within healthcare, biotech, AI, and SaaS. Their strategy emphasizes companies addressing large global markets with differentiated value propositions and strong management teams. Typical investment areas include high-performance semiconductors, cellular infrastructure, data analytics, therapeutics, and medical devices.
Notable portfolio companies include NorthSea Therapeutics, focused on therapeutics for NASH; Achronix Semiconductor Corporation, a supplier of eFPGA technology; Akarna Therapeutics, acquired by Allergan for small molecule therapy for NASH; and Biovex, acquired by Amgen for its oncolytic vaccine for melanoma. Other companies include Glydways, developing a high-capacity mobility system, and Ventyx Biosciences, focused on immunology.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.